Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and tolerability of oral Ixazomib in scleroderma-related lung disease was terminated, with results posted on 2025-04-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Michael M. Pham | Conditions: Systemic Sclerosis, Scleroderma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-06